Oral Anticoagulation 102: Identifying and Managing Risks




Presented by: Emily Persson, Pharm.D.

May 22, 2024



Quality Innovation Network -Quality Improvement Organizations CENTER 5 FOR MEDICARE & MEDICAI D SERVICES IQUALITY IMPRO VEMENT & INNOVATION GROU

Making Health Care Better Together



About Alliant Health Solutions



Tanya Vadala, Pharm.D.

MEDICATION SAFETY PHARMACIST

Tanya is an IPRO pharmacist with 20 years of experience in clinical pharmacy, community pharmacy, academia, quality improvement, and medication safety. Before joining IPRO, she worked at various community pharmacies and taught at Albany College of Pharmacy and Health Sciences in Albany, New York. She specializes in Medication Therapy Management (MTM), medication reconciliation, opioids, immunizations, and patient self-care. Her formal teaching experience includes courses in pharmacy practice and clinical experiential teaching.





Contact: <u>TVadala@ipro.org</u>

Emily Persson, Pharm.D.

PGY2 CARDIOLOGY PHARMACY RESIDENT

Dr. Persson earned her bachelor's degree in biochemistry from Suffolk University in Boston before becoming an environmental chemist. She later pursued her passion for helping individuals and the community through earning her Doctor of Pharmacy (PharmD) from Albany College of Pharmacy.

She completed her first year of postgraduate training as an inpatient pharmacy practice resident at Northern Light Eastern Maine Medical Center in Bangor, Maine, and is currently completing her second year of postgraduate training as a cardiology pharmacy resident at Capital Cardiology Associates in Albany, New York.





Contact: emily.persson@acphs.edu


Objectives

- Recall common indications for anticoagulation
- Recognize common drug-drug interactions with oral anticoagulants and the associated risks
- Identify ways to mitigate bleeding risk with oral anticoagulants
- Assess patient scenarios to identify medication-related problems in individuals taking oral anticoagulants

The content in this presentation was current as of April 17, 2024.



Common Oral Anticoagulation Medications (OAC)






Common Indications for OAC

Class	Drug	CAD/ ASCVD	Stroke (treatment & prevention)	VTE (treatment = X Prevention= #)
Vitamin K Antagonist	Warfarin		X	X/ #
	Apixaban		X	X/ #
Factor Xa Inhibitors	Rivaroxaban	X	X	X/ #
	Edoxaban		X	X
Direct Thrombin Inhibitor	Dabigatran		X	X/ #

Adapted from: Cabral K. Overview of Antithrombotic Therapeutics. Presentation at ACPHS. 2020.



Clotting Versus Bleeding Risk



Warfarin



Warfarin: Box Warning

Box Warning:

Warfarin can cause major or fatal bleeding. <u>Perform regular</u> <u>monitoring of international normalized ratio (INR) on all treated</u> <u>patients.</u> Drugs, dietary changes, and other factors affect INR levels achieved with warfarin therapy. Instruct patients about prevention measures to minimize the risk of bleeding and to report immediately to their health care provider signs and symptoms of bleeding.

<u>Blood testing methods</u>

- PT
- INR
- PTT



INR Goal

- Varies based on indication, patient history, and characteristics
- Dose of warfarin may be adjusted based on INR result
- For VTE and stroke prevention in atrial fibrillation:



INR can be affected by age, race/ethnicity, disease states, acute illnesses, diet and medications



Warfarin: Diet Interactions

Vitamin K-containing foods

- Brussel sprouts
- Collard greens
- Spinach
- Kale
- Parsley
- Broccoli
- Cabbage
- Liver
- Mayonnaise
- Oils

Image from: Vitamin K Rich Foods - Vaya News

Large portions over short periods of time may reduce anticoagulant effects




Encourage consistent vitamin K intake



Warfarin: Drug Interactions – Decreases INR

- Carbamazepine
- Phenytoin
- Rifampin
- Trazodone

- Sucralfate
- Cholestyramine





Warfarin: Drug Interactions – Increases INR

INR

- Anti-infective agents
 - Sulfamethoxazole/ trimethoprim (Bactrim)
 - Metronidazole
 - Fluconazole
 - Fluoroquinolones
 - Ciprofloxacin
 - Macrolides
 - Erythromycin
 - Azithromycin

- Acetaminophen
- Alcohol
- Amiodarone
- Cimetidine
- Thyroid hormone

CALLIANT QIN-QIO UAUNY INFORMATIONS HEALTH SOLUTIONS

Bleeding

Risk

Warfarin: Drug Interactions – Neutral Effect on INR

Some medications can increase the risk of bleeding without changing INR.

This is due to the synergistic effect of the medications together.

- COX-2 inhibitors (celecoxib)
- NSAIDS (ibuprofen, naproxen, indomethacin, ketorolac)
- Antiplatelets



Warfarin: Monitoring – Efficacy and Adverse Events

Frequent monitoring required

INR:

- Monitored at baseline and then about every few days (1-3)
- Once the dose is established and stable, can monitor less frequently
- If unstable or clinical changes, monitor more frequently
- At every INR draw, ask about
 - Adherence
 - Changes to medications
 - Changes to diet

Bleeding

- CBC (baseline and when warranted)



Managing Elevated INR – Warfarin Reversal

Bleeding Status	INR	Reversal Strategy	
Without bleeding	INR < 4.5	Lower or omit dose; monitor more frequently & resume warfarin at lower dose when INR therapeutic	
	INR > 4.5 to ≤ 10	Omit next 1-2 doses; monitor more frequently. OR Omit dose & give <u>vitamin K (1-2.5 mg orally)</u> – low risk of thromboembolism and greater risk of bleeding Resume an adjusted dose when INR in therapeutic range.	
	INR > 10	Hold warfarin therapy & give a higher dose of <u>vitamin K (2.5-5 mg orally)</u> Monitor in 24-48 hours & administer more vitamin K if necessary. Resume an adjusted dose when INR therapeutic.	
Significant bleeding	Any elevation of INR	Hold warfarin & give <u>vitamin K (10 mg IV) supplemented w/ fresh</u> frozen plasma (FFP) or 4-factor prothrombin complex concentrate (PCC). Can repeat vitamin K in 12 hours.	
Life-threatening bleeding		<u>1. 2.21</u> . editropedit monimit (in 12 meens)	



DOACs



Box Warnings: DOACs

Apixaban & rivaroxaban & dabigatran

- Premature discontinuation increases the risk of thrombotic events
- Spinal/Epidural hematomas
- Edoxaban
- Same as above
- Reduced efficacy in nonvalvular atrial fibrillation patients with CrCl > 95mL/minute



DOACs: Monitoring

Routine coagulation testing is **not** required or necessary for DOACs. No FDA-approved assays or calibration reagents are currently available.

Labs (baseline and when clinically indicated)

- CBC
- Serum creatinine
- Liver function tests



DOAC Dose Adjustments – Atrial Fibrillation

Class	Direct Thrombin Inhibitor		Factor Xa Inhibitor	
Name	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Renal dosing adjustments based on actual body weight	CrCl > 30 mL/min 150 mg twice daily	CrCl > 50 mL/min 20 mg daily with food	5 mg twice daily	CrCl > 95 mL/min Avoid use
				CrCl 51 - 95 mL/min 60 mg daily
	CrCl 15-30 mL/min 75 mg twice daily	CrCl 15-50 mL/min 15 mg daily with food	If 2 of the following: age ≥80 y	CrCl 15-50 mL/min 30 mg daily
			weight ≤60 kg SCr ≥1.5 mg/dL 2.5 mg twice daily	CrCl < 15 mL/min Avoid use



DOAC Use in Special Populations

Class		Direct Thrombin Inhibitor	Factor Xa Inhibitors		
Name		Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Dialysis		Contraindicated	May be used in atrial fibrillation but not recommended for other indications	Follow dosing recommendation from previous slide for atrial	Avoid use
Liver Fund	ction				
	Child-Pugh A	No dose adjustment needed			
	Child-Pugh B	Use with caution	Avoid use	Use with caution	Use with caution
	Child-Pugh C	Avoid use	Avoid use	Avoid Use	Avoid Use
Obesity		Patient weight > 120 kg or BMI ≥ 40 kg/m²: use other anticoagulants	No dose adjustments necessary	No dose adjustments necessary	Patient weight > 120 kg or BMI ≥ 40 kg/m ² : use other anticoagulants Bariatric and other GI surgery patients: evaluate risk vs benefit
Elderly		Age ≥ 75 y: Use with extreme caution or consider other treatment options (increased risk of GIB)	Avoid* long-term treatment of VTE or atrial fibrillation; safer alternatives preferred	Preferred agent in elderly	Consider dose reduction in patients age ≥ 80 or body weight ≤ 60 kg plus risk factors



DOAC: Drug Interactions

Class	Medication	Interactions	Effect	
	Apixaban	 Strong P-gp inhibitors and inducers CYP3A4 inhibitors and inducers 	 Dual CYP3A4 and P-gp inhibitors can increase effect 	
Oral factor Xa inhibitors	Rivaroxaban	 Strong P-gp inhibitors and inducers CYP3A4 inhibitors and inducers 	 CYP3A4 inducers and/or P-gp inhibitors can decrease effect 	
	Edoxaban	 Strong P-gp inhibitors and inducers 	 P-gp inhibitors increase effect 	
Direct thrombin inhibitor	Dabigatran	 Strong P-gp inhibitors and inducers 	P-gp inducers decrease effect	



DOAC: Drug Interactions – P-gp and CYP3A4

Class	Effect	Interactions	
P-gp	Inhibitors	 Amiodarone Clarithromycin Cyclosporine Erythromycin Ticagrelor 	 Itraconazole Ketoconazole Nicardipine Ritonavir Tacrolimus
	Inducers	 Carbamazepine Dexamethasone Phenytoin Fosphenytoin 	 Phenobarbital Rifampin St. John's Wort
СҮРЗА4	Inhibitors	 Clarithromycin Erythromycin Itraconazole Diltiazem 	 Cobicistat Nefazodone Ritonavir Voriconazole
	Inducers	CarbamazepineFosphenytoinPhenobarbital	PhenytoinRifampinPrimidone



Managing DOAC Bleeding

Agent	Reversal Strategy	
Oral factor Xa inhibitors • Apixaban • Rivaroxaban • Edoxaban	 Andexanet alfa (AndexXa) OR 4-factor PCC (Kcentra, Balfaxar) 	
Direct thrombin inhibitor • Dabigatran	 Idarucizumab (Praxbind) OR 4-factor PCC (Kcentra, Balfaxar) Dialyzable 	

Andexanet alfa boxed warning

- Thromboembolic risks, ischemic risks, cardiac arrest and sudden death
- 4-factor PCC boxed warning
- Arterial and venous thromboembolic complications

No boxed warning for idarucizumab




Bleeding Risk

- ISMP considers all anticoagulants as high-risk medications
- The Beers Criteria for potentially inappropriate medication use in older adults recommends the use of direct oral anticoagulants (calling out apixaban or dabigatran specifically) instead of rivaroxaban.
- Signs of bleeding due to anticoagulation:
 - Bruising
 - Blood in stool/urine
 - Coughing or vomiting up blood



Mitigating Bleeding Risk

- o Electric razors
- Non-slip socks/shoes
- Assisting patients with mobility issues
- Appropriate dosing
- Managing drug-drug interactions
- Periprocedural management
 - When to stop based on the pharmacokinetics of the medications prior to the procedure
 - DOACs usually two to three days prior to the procedure
 - Warfarin varies; maybe five to six days prior to the procedure or based on INR
 - When to start again based on the bleeding risk of the surgery
 - Appropriate use of bridging if necessary



Resources

- Warfarin. In: Lexi-drugs online [database on the Internet]. Waltham (MA): UpToDate Inc.; 2024 [updated 30 Apr 2024; cited 30 Apr 2024]. Available from: http://online.lexi.com. Subscription required to view.
- Apixaban. In: Lexi-drugs online [database on the Internet]. Waltham (MA): UpToDate Inc.; 2024 [updated 17 Apr 2024; cited 30 Apr 2024]. Available from: http://online.lexi.com. Subscription required to view.
- Rivaroxaban. In: Lexi-drugs online [database on the Internet]. Waltham (MA): UpToDate Inc.; 2024 [updated 24 Apr 2024; cited 30 Apr 2024]. Available from: http://online.lexi.com. Subscription required to view.
- Edoxaban. In: Lexi-drugs online [database on the Internet]. Waltham (MA): UpToDate Inc.; 2024 [updated 15 Apr 2024; cited 30 Apr 2024]. Available from: http://online.lexi.com. Subscription required to view.
- Dabigatran. In: Lexi-drugs online [database on the Internet]. Waltham (MA): UpToDate Inc.; 2024 [updated 24 Apr 2024; cited 30 Apr 2024]. Available from: http://online.lexi.com. Subscription required to view.
- Adexanet Alpha (Coagulation Factor Xa [Recombinant], Inactivated). In: Lexi-drugs online [database on the Internet]. Waltham (MA): UpToDate Inc.; 2024 [updated 24 Apr 2024; cited 30 Apr 2024]. Available from: http://online.lexi.com. Subscription required to view.
- Prothrombin Complex Concentrate (Human). In: Lexi-drugs online [database on the Internet]. Waltham (MA):
 UpToDate Inc.; 2024 [updated 4 Apr 2024; cited 30 Apr 2024]. Available from: http://online.lexi.com. Subscription required to view.
- Arnold M. J. (2024). Beers Criteria for Inappropriate Medication Use in Older Adults: Update From the American Geriatrics Society. *American family physician*, 109(4), 374–375.
- Hirsh J. (1998). Reversal of the anticoagulant effects of warfarin by vitamin K1. Chest, 114(6), 1505–1508.
 https://doi.org/10.1378/chest.114.6.1505







Making Health Care Better Together



Julie Kueker Julie.Kueker@AlliantHealth.org Alabama, Florida and Louisiana



Leighann Sauls Leighann.Sauls@AlliantHealth.org Georgia, Kentucky, North Carolina and Tennessee

Program Directors



ALABAMA • FLORIDA • GEORGIA • KENTUCKY • LOUISIANA • NORTH CAROLINA • TENNESSE



This material was prepared by Alliant Health Solutions, a Quality Innovation Network-Quality Improvement Organization (QIN – QIO) under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Publication No. 12SOW-AHS-QIN-QIO TO1-NH--5690-05/01/24

